M. M. Shen

This study uses scRNA-seq data from mouse and human prostate tissues to show epithelial plasticity in regression, regeneration, and cancer, with findings on cell type origins and AR signaling heterogeneity.

This study identifies NSD2 as a key driver of lineage plasticity and castration-resistance in neuroendocrine prostate cancer, showing its inhibition can restore sensitivity to AR inhibitors.

The paper uses multi-omics single-cell data to define the epigenetic basis of castration-resistant prostate luminal cells in mice and identifies key molecular pathways involved.

OncoLoop predicts and validates drug sensitivity in tumors and their models by leveraging perturbational profiles of oncology drugs, showing success in prostate cancer models and patient cohorts.

This study identifies non-canonical Activin A signaling as a mechanism maintaining prostate epithelial progenitor quiescence, with implications for cancer and therapy.